All In Biotech

Drug Trial Radar · NCT04718389

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,717

Actual

Start

Jan 26, 2021

Primary completion

Sep 14, 2025

Study completion Sep 14, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.

Conditions

  • Asthma

Interventions

  • GSK3511294 (Depemokimab)Biological

    GSK3511294 (Depemokimab) 100 mg SC along with the placebo and SOC will be administered.

  • MepolizumabBiological

    Mepolizumab 100 mg SC will be administered in a single-use PFS.

  • BenralizumabBiological

    Benralizumab 30 mg will be administered in a single-use PFS.

  • PlaceboBiological

    Placebo will be a sterile liquid formulation.

  • Standard of care (SoC)Drug

    Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).

  • Pre-filled Syringes (PFS)Device

    PFS will include glass barrel with pre-staked needle and plunger.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Clinically Significant Exacerbations Over 52 WeeksTime frame: Up to Week 52

Locations

397 sites in 21 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Scottsboro, Alabama

  • GSK Investigational Site

    Litchfield Park, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Oxnard, California

  • GSK Investigational Site

    Rancho Cucamonga, California

  • GSK Investigational Site

    Redondo Beach, California

  • GSK Investigational Site

    Redwood City, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Valencia, California

  • GSK Investigational Site

    Woodland, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Kissimmee, Florida

  • GSK Investigational Site

    Loxahatchee Groves, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

Showing 40 of 397 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.